The stock of Enzymotec Ltd (NASDAQ:ENZY) reached all time low today, Nov, 16 and still has $5.12 target or 11.00% below today’s $5.75 share price. This indicates more downside for the $115.40M company. This technical setup was reported by Barchart.com. If the $5.12 PT is reached, the company will be worth $12.69M less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. About 78,926 shares traded hands or 467.32% up from the average. Enzymotec Ltd (NASDAQ:ENZY) has declined 30.16% since April 14, 2016 and is downtrending. It has underperformed by 34.85% the S&P500.
Enzymotec Ltd (NASDAQ:ENZY) Ratings Coverage
Out of 3 analysts covering Enzymotec (NASDAQ:ENZY), 2 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 67% are positive. Enzymotec has been the topic of 4 analyst reports since August 13, 2015 according to StockzIntelligence Inc. The rating was upgraded by Wells Fargo on Thursday, August 13 to “Outperform”.
According to Zacks Investment Research, “Enzymotec, Ltd. provides specialty lipid-based products and solutions. The Company develops, manufactures and markets bio-functional lipid ingredients as well as final products. It serves pharmaceuticals and nutrition industries worldwide. Enzymotec, Ltd. is based in Migdal HaEmeq, Israel.”
More recent Enzymotec Ltd (NASDAQ:ENZY) news were published by: Globenewswire.com which released: “Enzymotec Ltd. Announces Departure of its CEO” on November 16, 2016. Also Reuters.com published the news titled: “BRIEF-Enzymotec Ltd. announces departure of its CEO” on November 16, 2016. Globenewswire.com‘s news article titled: “Enzymotec Ltd. Announces Investigator Initiated Clinical Trial of Vayarin(R …” with publication date: July 07, 2015 was also an interesting one.
ENZY Company Profile
Enzymotec Ltd., incorporated on March 8, 1998, is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Firm operates in two divisions: Nutrition segment and VAYA Pharma segment. Both of the Company’s divisions offer a range of products that leverage its lipid-related offerings. The Company’s product suite addresses the entire human life-cycle, from infancy to old age, and comprises ingredients in products ranging from infant formula to nutritional supplements, as well as branded medical foods, sold only under a doctor’s supervision. It markets its product portfolio to established global consumer companies and physicians and target large and growing consumer health and wellness markets. The Company’s clinically-validated products include bio-functional lipid compounds designed to address dietary needs, medical disorders and common diseases. The Company’s technologies enable it to identify appropriate lipid-modifying enzymes and then improve the activity of these enzymes, as well as to enable their use in organic media. These enzymes are then utilized to restructure lipids found in natural sources, including krill, fish, vegetable sources and bovine milk.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.